Viridian Therapeutics, Inc. (VRDN) — Stock Score Summary

Viridian Therapeutics, Inc. (VRDN) has a MoatMap StockRank of 5/100 based on Quality (29/100), Value (36/100), and Momentum (18/100) factor scores. The current signal is STRONG SELL.

Viridian Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for serious and rare diseases, with a primary emphasis on thyroid eye disease (TED). The company's lead product candidate, VRDN-001, is an anti-IGF-1R antibody designed for rapid and potent efficacy in TED patients. Its focused development strategy targets high unmet medical needs, aiming to capture a significant share of a specialized therapeutic market.

Key Financial Metrics

Price$17.24
Market Cap$1.9B
P/E (Forward)-6.36
Price/Book2.76
Return on Equity-58.1%
Return on Invested Capital-40.7%
Debt/Equity8.39
Gross Margin0.0%
Operating Margin-82389.4%
Revenue Growth95.8%
Free Cash Flow$-183M

Viridian Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Viridian Therapeutics, Inc.’s (VRDN) StockRank?
MoatMap’s StockRank for Viridian Therapeutics, Inc. (VRDN) is 5/100, with a Strong Sell signal. It is a composite of Quality (29), Value (36), and Momentum (18) factor ranks across MoatMap’s 19,000+ stock universe.
Does Viridian Therapeutics, Inc. have an economic moat?
Viridian Therapeutics, Inc. (VRDN) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Viridian Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Viridian Therapeutics, Inc. (VRDN) is Strong Sell, based on a StockRank of 5/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Viridian Therapeutics, Inc. in?
Viridian Therapeutics, Inc. (VRDN) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksVRDN deep dive reportAI ChampionsHow we score stocksSense-check another stock